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Genome-wide association study of developmental
dysplasia of the hip identifies an association with
GDF5
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Developmental dysplasia of the hip (DDH) is the most common skeletal developmental
disease. However, its genetic architecture is poorly understood. We conduct the largest DDH
genome-wide association study to date and replicate our findings in independent cohorts. We
find the heritable component of DDH attributable to common genetic variants to be 55% and
distributed equally across the autosomal and X-chromosomes. We identify replicating evi-
dence for association between GDF5 promoter variation and DDH (rs143384, effect allele A,
odds ratio 1.44, 95% confidence interval 1.34–1.56, P= 3.55 × 10−22). Gene-based analysis
implicates GDF5 (P= 9.24 × 10−12), UQCC1 (P= 1.86 × 10−10), MMP24 (P= 3.18 × 10−9),
RETSAT (P= 3.70 × 10−8) and PDRG1 (P= 1.06 × 10−7) in DDH susceptibility. We find
shared genetic architecture between DDH and hip osteoarthritis, but no predictive power of
osteoarthritis polygenic risk score on DDH status, underscoring the complex nature of the
two traits. We report a scalable, time-efficient recruitment strategy and establish for the first
time to our knowledge a robust DDH genetic association locus at GDF5.
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Developmental dysplasia of the hip (DDH) is a disordercharacterised by abnormal development of the hip jointand presents with varying severity from mild uncovering
of the femoral head to complete dislocation of the joint1. It is the
most common developmental musculoskeletal anomaly, with
population-weighted average incidence that ranges strongly with
ethnic background from 0.06 per 1000 live births in Black Afri-
cans to 76.1 per 1000 live births in Native Americans2, and with
an incidence in the UK European population of 3.6 per 1000.
DDH is a complex disorder, with known associations including
female sex, first-born, breech presentation, and family history2.
There is a seven-fold increase in the incidence between siblings
and a 10-fold increase in the parents of probands compared to the
general population3, and a concordance rate of 41% between
identical twins versus 3% in dizygotic twins4.
While DDH is heritable, its genetic architecture remains poorly
characterised. Several linkage scans and candidate gene studies
have implicated possible associated genetic variants, including in
GDF55, but to date no replicated loci of genome-wide significance
have been identified2,6–9. A recent genome-wide association study
(GWAS) of 386 patients and 558 controls in the Han Chinese
population suggested an association with variation in UQCC
(odds ratio (OR) 1.35, P= 3.63 × 10-6), a gene adjacent to
GDF510. Morphological abnormalities of the hip such as DDH are
also recognised as risk factors for the development of secondary
degenerative change of the hip11,12, and commonly result in hip
replacement in adult life12,13. Idiopathic hip osteoarthritis is also
very common and has a substantial heritable component14, and
may share common genetic aetiology with DDH2,7,15.
Systematic examination of genome-wide variation in DDH in
larger sample sizes is necessary to clarify its heritable biology and
inform mechanism-driven preventative strategies. However,
sample collection for uncommon diseases can be challenging and
time-consuming, as attested by the relative paucity of sample sets
for genetic studies of DDH. Routinely collected national clinical
audit datasets present an opportunity for efficient case ascer-
tainment in genetic epidemiology. The National Joint Registry for
England, Wales, Northern Ireland, and the Isle of Man (NJR,
http://www.njrcentre.org.uk/) was established in 2003 to collect
audit data on all hip and knee replacement surgery in these
regions, for which it has a completeness rate of 97% (http://www.
njrreports.org.uk/Data-Completeness-and-quality). As at 31
December 2014, the dataset held information on 711,765 primary
hip replacement procedures, including data on the diagnostic
indication for surgery.
We use the NJR as a case-ascertainment tool to conduct a
nationwide genome-wide association scan to characterise the
genetic architecture of DDH. We examine the heritable con-
tribution to DDH, and use fine-mapping and gene-based
enrichment approaches to identify likely causal variants and
genes. Finally, we use independent osteoarthritis datasets to
examine the potential for shared genetic aetiology between DDH
and hip osteoarthritis. We report a scalable, time-efficient
recruitment strategy. We find the heritable component of DDH
attributable to common variants to be 55% with the lead repli-
cating signal at genome-wide significance being rs143384 within
the GDF5 promoter. We also find shared genetic architecture
between DDH and hip osteoarthritis.
5411 NJR ‘hip dysplasia’ cases sent DDH
history and ancestry questionnaire
2668 responders
1091 DDH cases sent
saliva DNA kit
907 completed saliva
DNA kits returned
900 samples
progressed to DNA
extraction
770 DDH cases used
for Coreexome array
discovery analysis
66 DDH cases with low
DNA yield used for
replication analyses
25% subset radiographic validation,
n =7 non-DDH subjects excluded
Non-UK European ancestry
or non-DDH history, n =1570 excluded
Coreexome beadchip
quality control, n =64
samples excluded
Fig. 1 Recruitment flowchart
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Results
Recruitment strategy. At the time of recruitment, the NJR had
“hip dysplasia” recorded as the indication for hip replacement
surgery in 5411 patients from the total database of 711,765 pro-
cedures (0.76%). All of these individuals were invited to partici-
pate in the postal screening phase of the study (Fig. 1). Following
screening, 1091 consenting individuals with self-confirmed UK
European ancestry and idiopathic DDH diagnosed in childhood
were invited to submit a saliva sample. Of the 907 who returned a
sample, 834 provided sufficient DNA to proceed to genome-wide
genotyping. After quality control, 64 more individuals were
excluded, leading the final number of DDH cases used in the
genome-wide association analysis to 770. The sex distribution of
the responding subjects was similar to that of the DDH popula-
tion in the UK4. The diagnosis of DDH was independently vali-
dated by assessment of pelvic radiographs in a convenience
sample of 25% of the subjects completing saliva return. The age
and sex distribution of the radiographic validation subset was
similar to the 907 that returned a saliva sample and radiographic
analysis confirmed DDH in 224/231 (97%) subjects. Non-DDH
cases were excluded from further analysis. The time taken from
first patient mailshot to completion of genome-wide association
analysis was approximately 18 months.
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Fig. 2 Manhattan and quantile–quantile plot of the DDH genome-wide association scan. a The dashed line indicates the genome-wide significance
threshold (P= 5.0 × 10-8). Green dots represent variants for which P-values reached the genome-wide significance threshold and red dots illustrate the
other two replicating signals. Chromosomes X and pseudo-autosomal regions on the chromosome X are represented by number 23 and 24, respectively.
b Quantile–quantile plot of the data used in the GWAS
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Controls were drawn from the United Kingdom Household
Longitudinal Study (UKHLS), also known as Understanding
Society (http://www.understandingsociety.ac.uk/). The UKHLS is
an annual longitudinal panel survey of over 40,000 UK house-
holds from England, Scotland, Wales and Northern Ireland
beginning in 2009–2010. Participants are surveyed annually and
the study includes a wide range of sociodemographic, phenotypic,
self-reported medical history and medication use data. Biomedi-
cal measures and blood samples were collected during a single
nurse visit and DNA has been extracted and stored for genetic
analyses. In total, 10,480 samples were genotyped on the Illumina
HumanCoreExome-12v1-0_A chip at the Wellcome Trust Sanger
Institute. After quality control (QC), genotype data for 9961
individuals were available. We further excluded all participants
with any musculoskeletal disorder and the final dataset comprised
8016 individuals. A case:control ratio of ~1:4 was selected to be
used in both discovery and replication stage to guard against case:
control imbalance causing association tests to miscalculate for low
frequency variants16.
The heritable component of DDH. Using genetic complex trait
analysis (GCTA)17 across 770 cases and 3364 controls in the
discovery GWAS, we found that common-frequency autosomal
single-nucleotide polymorphisms (SNPs) explain 55% (±se= 6%,
P < 0.0001) of the liability-scale heritability of DDH (Supple-
mentary Table 1). The heritability estimate was similar (54.7 ±
5.8%) when the analysis was repeated using sex as a covariate.
When the heritability analysis was stratified by chromosome, we
found that the X chromosome contributed a similar amount to
overall DDH heritability as each of the autosomes (Supplementary
Fig. 1), and we identified no individual X-chromosome signals.
Discovery GWAS. Genome-wide likelihood ratio test under an
additive genetic model for association with DDH showed an
excess of signals in the discovery sample set (Fig. 2a, b). Data were
pruned for linkage disequilibrium using the clumping function in
PLINK and 53 SNPs comprising 25 independent signals showed
suggestive evidence for association with DDH with P < 1 × 10−4
compared to three independent variants expected under the null
hypothesis of no association (binomial P= 9.57 × 10−17, Sup-
plementary Table 2). Eleven correlated variants reached genome-
wide significance (P < 5.0 × 10−8) and all reside in the same
region. The lead variant, rs143384 (effect allele A, effect allele
frequency (EAF) 0.60, OR [95% CI] 1.57 [1.3–1.77], P= 1.72 × 10
−14), is located in the 5′ untranslated region (UTR) of GDF5
(20q11.22). We performed a conditional analysis specifically for
rs143384 and rs143383 (effect allele A, EAF 0.64, OR [95% CI]
1.51 [1.33–1.70], P= 1.29 × 10−11) as they have both previously
shown suggestive association with DDH. When rs143383 is
conditioned on rs143384, the P-value becomes insignificant
((effect allele A, EAF 0.64, OR [95% CI] 1.51 [1.33–1.70], P=
0.61), suggesting the association observed with rs143383 is not an
independent signal. Since DDH is more prevalent in women, we
also repeated the analysis using sex as a covariate and found no
qualitative difference in the results (Supplementary Table 3).
Replication. Independent association signals were taken forward
to replication in three DDH cohorts of UK European ancestry,
totalling 1129 cases and 4652 UKHLS controls. Following QC,
one of the variants was excluded from further analysis due to low
call rate. Five SNPs showed evidence for nominally significant (P
< 0.05) association with the same direction of effect as the dis-
covery cohort, compared with 1.35 under the null expectation
(binomial test P= 0.01; Supplementary Table 4). rs143384
reached genome-wide significance in the replication dataset alone
(effect allele A, EAF 0.61, OR [95% CI] 1.37 [1.24–1.51], P=
1.33 × 10−10). When the replication analysis was performed
excluding the 66 NJR subjects that failed genome-wide genotyp-
ing QC, the findings were similar.
Meta-analysis. Twenty SNPs had the same direction of effect in
both the discovery and replication analysis. Upon meta-analysis,
three SNPs in the same region of chromosome 20 showed asso-
ciation with DDH at genome-wide significance: rs143384 in
GDF5 (effect allele A, OR [95% CI] 1.44 [1.34–1.56], P= 3.55 ×
10−22; Fig. 3a) rs12479765 in MMP24 (effect allele G, OR [95%
CI] 1.33 [1.20–1.47], P= 3.18 × 10−8), and rs2050729 in RMB39
(effect allele G, OR [95% CI] 1.41 [1.25–1.58], P= 1.15 × 10−8).
Conditional analysis of rs12479765 and rs2050729 on the lead
variant rs143384 attenuated their association with DDH.
Although the linkage disequilibrium (LD) r2 correlations among
these three variants are lower than 0.16 (Supplementary Table 5),
the P-values after conditioning on rs143384 were P= 0.004 and
P= 0.045 for rs2050729 and rs12479765, respectively, suggesting
residual nominal independent association of these variants with
DDH. Rs143384 explained 0.96% of DDH variance on the lia-
bility scale (h2L) and the sibling relative risk ratio (λs) attributable
to this variant was λs= 1.04 (Supplementary Fig. 2).
Two further independent signals showed evidence of replicat-
ing association with DDH, although they did not reach genome-
wide significance at meta-analysis: rs4740554 (effect allele C, EAF
0.10, OR [95% CI] 1.30 [1.16–1.45], P= 4.44 × 10−6) and
rs4919218 (effect allele C, EAF 0.31, OR [95% CI] 1.19
[1.10–1.28], P= 4.38 × 10−6; Fig. 3b, c; Table 1). rs4740554 and
rs4919218 explained 0.36% and 0.24% of phenotypic variance (λs
= 1.02 and 1.01), respectively (Supplementary Fig. 2).
Fine-mapping. For the GDF5 signal, the sum of probabilities of
causality for five variants in the fine-mapped region was ≥0.95.
Among these, both rs143384 and rs143383 have high epigenomic
scores as they are located in the 5′ UTR of GDF5, have high
nucleotide sequence conservation, and overlap DNase hypersen-
sitivity and activating histone marks. Considering annotations
and association P-values together, rs143384 had a >99% like-
lihood of being the causal variant, assuming only one variant as
causal. For the other two replicating signals it was not possible to
narrow down the location of the likely causal variants, as the
chr10 and chr9 locus credible sets contain 483 and 618 variants,
respectively.
Gene-based analyses. We performed gene-based analysis using
MAGMA v1.03 (ref. 18) to identify genes which contain multiple
variants that contribute to DDH. Prior to gene analysis, MAGMA
applies an internal SNP QC process. MAGMA uses all remaining
SNPs in a gene to compute gene P-values while accounting for LD
and after adjusting for the family-wise error rate (FWER). We
Fig. 3 Regional association plots of the three replicating signals. Regional association plot of rs143384 (20:34025756) (a), rs4740554 (9:13688437) (b)
and rs4919218 (10:100111392) (c). Each filled circle represents the P-value of analysed variants (as −log10 P-values) plotted against their physical position
(NCBI Build 37). The P-value at the discovery stage and combined discovery and replication cohorts is represented by a purple circle and diamond,
respectively. The other variants in the region are coloured depending on their degree of correlation (r2) with the index variant according to a scale from r2
= 0 (blue) to r2= 1 (red). Gene location is annotated based on the UCSC genome browser
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found five genes that were significantly associated with
DDH susceptibility: GDF5, UQCC1, MMP24, RETSAT and
PDRG1 (P= 9.24 × 10−12, P= 1.86 × 10−10, P= 3.18 × 10−9,
P= 3.70 × 10−8 and P= 1.06 × 10−7, respectively). Following
QC, 13, 18, 17, 20 and 6 SNPs were included in the analysis for
GDF5, UQCC1, MMP24, RETSAT and PDRG1, respectively
(Supplementary Fig. 3). To exclude association through GDF5, we
repeated the analysis by removing GDF5 and all genes remained
significantly associated with DDH. We further looked up the
functionality of the variants that were used in the analysis for
each gene to better understand whether their effects are local to
the gene itself, or may have more distant regulatory effects. Over
59% of these remaining variants in each gene analysed by
MAGMA are assumed to have high (disruptive) impact in the
protein (e.g. missense, stop codon) (Supplementary Fig. 3) and
none of the significant genes share variants that are in high LD
with each other across genes (Supplementary Table 6). Fourteen
variants are expression quantitative trait loci (eQTL) that regulate
various genes nearby (Supplementary Data 1).
Genetic overlap with hip osteoarthritis. We calculated polygenic
risk scores to detect shared genetic aetiology between DDH and
hip osteoarthritis. We found no evidence that hip osteoarthritis
polygenic risk score predicts DDH status. The best-fit polygenic
risk score for hip osteoarthritis in the arcOGEN19 and in the UK
Biobank (UKBB) International Classification of Diseases (ICD)
10 coded hip osteoarthritis datasets explained ~0.05% and 0.35%
of variation in DDH susceptibility, respectively (FWER P > 0.05;
Supplementary Fig. 4A, B). To further investigate the genetic
overlap with hip osteoarthritis, we utilised LD score regression
(LDSC)20 to estimate the genetic correlation between DDH and
UKBB hip osteoarthritis datasets. DDH showed a nominally
significant positive genetic correlation (rg) with hip osteoarthritis
(rg= 0.5839, s.e.= 0.2068, P= 0.0047). However, this finding
does not distinguish between shared genetic causes and a genetic
causal relationship between the two traits. We also calculated the
genetic correlations between DDH and 235 other traits and dis-
eases using GWAS summary statistics and LD score regression
implemented in the online software LD Hub21. After applying the
false discovery rate (5% FDR) procedure to correct for multiple
testing, none of the traits/diseases had a significant genetic cor-
relation with DDH (Supplementary Data 2). We found a nom-
inally significant genetic correlation with citrate (rg= 0.5934, s.e.
= 0.2211, P= 0.0073), acetate (rg=−0.6778, s.e.= 0.2545, P=
0.0077), birth weight (rg= 0.2399, s.e.= 0.1104, P= 0.0298),
infant head circumference (rg= 0.3932, s.e.= 0.1826, P= 0.0313)
and child birth weight (rg= 0.3576, s.e.= 0.1815, P= 0.0488)
which did not pass multiple-testing correction.
Discussion
We used case-ascertainment by national clinical audit database
search and postal recruitment to facilitate the largest genome-
wide association scan for DDH to date. We find that the
heritable component of DDH due to common autosomal variants
is approximately 55%, consistent with the complex nature of
the disease, and find evidence for genetic correlation but a lack
of predictive power of osteoarthritis polygenic risk scores
on DDH. We establish variation within GDF5 on chromosome 20
as robustly associated with DDH susceptibility with rs143384 as
the causal signal by fine-mapping, although GDF5 variation
makes only a small contribution to overall DDH heritability.
Through gene-based analyses we identify GDF5, UQCC1,
MMP24, RETSAT and PDRG1 to be associated with DDH
susceptibility.
The patients recruited in the discovery cohort were adults with
a diagnosis of hip dysplasia ascertained via a national clinical
audit database for hip replacement. We employed a stepwise fil-
tration approach to mitigate misclassification bias in case ascer-
tainment, using indication for surgery recorded in the NJR
followed by self-reported questionnaires for phenotype con-
firmation. The discovery cohort studied here may reflect indivi-
duals with either untreated DDH or who have had treated disease
eventually leading to the need for hip arthroplasty, resulting in
potential selection bias. In mitigation against this, the female to
male case ratio in our final NJR DDH cohort was similar to that
expected in the general DDH population in the UK2, and con-
trasts with the sex ratio found in the population with idiopathic
osteoarthritis of the hip22. The case filtration approach used was
also validated with high concordance by examination of plain
radiographic images acquired through the National Data Sharing
Network. Ancestry screening by questionnaire in this population
also resulted in only a small percentage of outliers requiring
exclusion by genotyping. Finally, our replication cohorts mainly
comprised independent populations of children recruited pro-
spectively with a firm diagnosis of DDH, and in whom the EAF
and odds ratio of association for the primary variant signal was
almost identical as that found in the NJR discovery sample. DDH
is a risk factor for degenerative disease at the hip11,12,23, and
osteoarthritis susceptibility genes influence the association
between hip morphology and osteoarthritis15,24,25. We therefore
also examined whether we were simply detecting osteoarthritis-
associated genetic loci in our DDH discovery cohort, as case
identification required NJR registration for a hip replacement.
Polygenic risk scores derived using independent hip osteoarthritis
cohorts predicted only a small amount of the genetic variability in
the DDH discovery population. However, using LDSC we found a
58% positive genetic correlation between the two diseases. The
main difference between the two analyses is that PRS uses var-
iants under a specific P-value threshold where LDSC uses
genome-wide summary statistics. Although LDSC is a method to
estimate the degree to which genetic risk factors are shared
between two diseases or traits, it does not ascribe causation. Thus
the observed correlation might be attributed either to shared
genetic effects on both traits or because of causal pathways
between traits. Moreover, it’s not clear if one variable is causal to
Table 1 Replicating variants associated with DDH
SNP ID
(chromosome:
position)
Effect allele/
other allele
Effect allele
frequency
(discovery stage)
Discovery odds
ratio (95% CI)
Discovery
P-value
Replication odds
ratio (95% CI)
Replication
P-value
Meta-analysis
odds ratio
(95% CI)
Meta-
analysis
P-value
rs143384
(20:34025756)
A/G 0.60 1.57 (1.40–1.77) 1.72 × 10−14 1.37 (1.24–1.51) 1.33 × 10−10 1.44 (1.34–1.56) 3.55 × 10−22
rs4740554
(9:13688437)
C/A 0.10 1.44 (1.22–1.71) 4.09 × 10−05 1.20 (1.03–1.39) 0.01 1.30 (1.16–1.45) 4.44 × 10−6
rs4919218
(10:100111392)
C/T 0.69 1.27 (1.13–1.43) 6.48 × 10−05 1.14 (1.03–1.25) 0.0089 1.19 (1.10–1.28) 4.38 × 10−6
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the other or if causation is mediated by an independent factor.
Future studies using Mendelian randomisation analyses may
determine the causal relationships between DDH and hip
osteoarthritis.
Previous studies examining the epidemiology of DDH within
families using linkage approaches have demonstrated that heri-
table factors contribute between 50% and 85% of the total risk or
liability of disease3,26,27, depending on population ancestry. Here,
we used dense genome-wide genotyping data to estimate the
heritable risk of DDH among unrelated individuals of UK Eur-
opean ancestry in the general English population. Our estimate of
DDH heritability attributable to variation within common auto-
somal chromosomes was broadly similar to the estimates derived
from linkage analyses, and confirms the complex nature of the
disease2. Although DDH shows strong sexual dimorphism, the
heritability estimate was almost identical (54.7 ± 5.8%) when the
analysis was repeated using sex as a covariate. When the herit-
ability analysis was stratified by chromosome, we found that the
X-chromosome contributed a similar amount (adjusted for
length) to overall DDH heritability as the autosomes (Supple-
mentary Fig. 1), and we identified no individual chromosome X
signals. We also conducted the discovery association analyses
both with and without adjustment for sex (Supplementary
Tables 2 and 3), and this made no qualitative difference to the
results. Taken together, these data suggest that although DDH is a
strongly sex-linked condition, this is not substantially due to
variation in genomic DNA.
The gene GDF5 encodes growth differentiation factor 5
(GDF5), belonging to the transforming growth factor beta
superfamily28. GDF5 is required for normal bone and joint
development by promoting cartilage condensation and increasing
the size of the skeletal elements through proliferation within
epiphyseal cartilage29. Two GDF5 variants, rs143383 and
rs143384, have previously shown suggestive association with
DDH in unreplicated candidate gene studies in Asians and in
Europeans5,30. Here we validate and extend these findings at the
genome-wide level and with robust replication. These variants are
in high linkage disequilibrium (r2= 0.82, D′′= 0.99), and were
both directly genotyped in this study. Our data implicate
rs143384 as the lead variant, with the rs143383 association with
DDH being two orders of magnitude weaker. Conditional ana-
lyses substantiate this observation.
We identify an extended region of 16 DDH-associated
variants at genome-wide significance and in high LD extending
across GDF5 and UQCC, with rs143384 as the lead signal.
Interrogation of the GTEx database indicates that rs143384 is an
eQTL for multiple genes across various tissues (Supplementary
Table 7)31,32. Recently, Chen et al.33 have shown that the GDF5
locus contains many separate regulatory elements that control
expression of the gene at different joint sites, and that these
flanking regions are large. The same group have since described a
novel enhancer region GROW1 in an extended downstream
regulatory region of GDF534. The lead variant in this 5′ enhancer
is rs4911178 (Chr:Pos 20:33952620), a G > A substitution in
which the variant allele A occurs at high frequency in Eurasian
populations, and in which DDH and osteoarthritis are also
common34. This variant was also directly typed in our discovery
cohort, and identified in our extended association region on
chromosome 20 (Supplementary Table 3). The effect allele G (OR
0.67, 95% CI 0.59–0.76, P= 2.98 × 10−11) was in strong LD (r2=
0.8) with rs143384, consistent with the findings of Capellini
et al.34. This annotated function provides novel opportunities for
investigation of the role of GDF5 as a candidate target for DDH
prevention.
Gene-based enrichment analysis can boost power to identify
contributing loci by combining information across multiple SNPs
co-localised at the gene level. We found significant associations
between DDH and the GDF5, UQCC1, MMP24, RETSAT and
PDRG1 genes. The results of functional look up, LD calculations
and after removing the GDF5 locus from the analysis, tie the
association to the above genes. However, these results refer only
to the variants used in the gene-based analysis and further
investigation through functional experiments is warranted to
asses if these signals are truly independent. UQCC1 gene encodes
a trans-membrane protein ubiquinol-cytochrome-c reductase
complex chaperone, which is structurally similar to the mouse
basic fibroblast growth factor repressed ZIC-binding protein.
UQCC is expressed in differentiating chondrocytes and regulates
growth control in mouse35,36. In humans, polymorphisms in this
gene are associated with DDH10, bone size37, height38 and hip
axis length39. MMP24 encodes a member of the peptidase M10
family of matrix metalloproteinases (MMPs) which are involved
in the breakdown of extracellular matrix in normal physiological
processes, such as embryonic development and tissue remodel-
ling40. Polymorphisms within MMP24 have also been associated
with height variation in childhood41,42. RETSAT codes for retinol
saturase, an enzyme centrally involved in the metabolism of
vitamin A43. Retinoic acid signalling is essential for normal limb
bud development, including bone and cartilage formation44. The
RETSAT pathways provides a further candidate therapeutic target
for the prevention of DDH.
In conclusion, this largest study of DDH to date provides a
comprehensive picture of its complex genetic architecture,
the contribution of common variants to its heritability, and
establishes the first robust DDH genetic locus to our knowledge.
We demonstrate proof of principle for the utility of national
clinical audit-based case ascertainment and recruitment for
genetics and genomics studies using a strategy that is readily
transferrable to other complex diseases in which large-scale
datasets are held.
Methods
Study oversight. The study was approved by the National Research Ethics Service
in England (NRES 12/YH/0390, 30 October 2012). Initial contact was made by the
NJR data controller and all subjects provided written informed consent prior to
participation.
Study populations. National Joint Registry (NJR) cohort: The NJR hip dysplasia
base population comprised 5411 adult individuals (4095 females) living in England
who had undergone a hip replacement recorded in the NJR by the operating
surgeon as being for the indication of hip dysplasia and who had given written
permission for re-contact for research purposes. All were invited to participate in
the postal screening phase of the study between January 2013 and April 2014
(Fig. 1, recruitment flowchart). Screening for UK European descent was made
using self-declared ancestry as: White European, Black African, Black Caribbean,
Asian, Arabic, Chinese/Oriental, Mixed, or Other; and supplemented by country of
birth, mother’s country of birth, and father’s country of birth. A further check for
ethnicity outliers was made at genotyping, where DNA samples proceeded to
analysis. DDH history was confirmed by self-completed questionnaire (Supple-
mentary Table 8). Inclusion required a positive response to both question 1 and 2.
Subjects responding positively to any items within questions 6, 7 or 10 were
excluded from further participation. One thousand and ninety-one individuals
confirming both UK European ancestry and idiopathic DDH diagnosed in child-
hood were invited to return by post a saliva sample for DNA extraction and
genotyping. Nine hundred and seven subjects (mean age 51.6 ± 12.4 years; 803
(88%) females) returned a saliva sample for DNA processing. The sex distribution
of the subjects returning a sample was similar to that of the DDH population in the
UK2. In 231 subjects (mean age 51.6 ± 12.4 years; 211 (91%) females) operated in
hospitals from which >10 cases were recruited and independent radiographic
validation of the DDH phenotype was made following retrieval of the pelvic
radiograph preceding hip replacement using the National Data Sharing Network
(http://www.image-exchange.co.uk/). The images were reviewed independently by
two experienced orthopaedic surgeons for the presence and grade of DDH using
the Hartofilakidis45 classification. A third observer made the final judgement if
there was disagreement. This analysis confirmed DDH in 224 (97%) of subjects.
Eighty had radiographic evidence of a previous corrective pelvic and/or femoral
osteotomy that precluded DDH grade classification beyond confirmation of the
DDH phenotype. Of the remaining 151 subjects, 77 showed Hartofilakidis grade A
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dysplasia (femoral head contained within the original acetabulum despite the
degree of subluxation), 48 were of grade B (low dislocation, femoral head articu-
lates with a false acetabulum that partially covers the true acetabulum to a varying
degree), and 31 were of grade C (high dislocation, femoral head is completely out of
the true acetabulum and migrated superiorly and posteriorly to a varying degree).
Seven subjects were excluded from further analysis, and all had a radiographic
phenotype of idiopathic osteoarthritis. This distribution of disease grades was
consistent with expectation of an adult patient cohort with a history of childhood
DDH2,46,47. The mean age of the 770 subjects (693, 90% females) participating in
the discovery GWAS was 50 ± 12 years.
DDH case control cohort: This population comprised 838 children (725 female)
mean age 7 ± 5 years recruited by face-to-face contact at 1 of 18 participating
hospitals (see related manuscript file) and undergoing hospital treatment for DDH,
or currently under follow-up for hospital-treated DDH. These subjects had been
previously diagnosed with DDH by patient history and clinical examination in
conjunction with radiography or ultrasonography. Subjects with borderline forms
of DDH, such as a brief episode of harness treatment for mild instability, were
excluded. None of the participants in the DDH case control cohort have undergone
hip replacement and are therefore independent of the participants in the NJR
cohort.
Royal National Orthopaedic Hospital (RNOH) cohort: The subjects within this
cohort comprised 225 adults (220 female), mean age 32 ± 16 years participating in
the RNOH DDH biobank, with a clinician-confirmed childhood history of
idiopathic DDH by patient history and clinical examination in conjunction with
radiography or ultrasonography, and undergoing osteotomy for residual dysplasia
and/or degenerative changes. Subject level identification checks between the
participants in the RNOH versus NJR adult recruitment cohorts was used to
exclude any subject overlap between the cohorts.
The replication cohort comprised the 838 children from the UK DDH case
control consortium (DDH CCC) and the 225 adults with DDH recruited in the
RNOH DDH biobank. In addition, 66 cases (59 female) from the NJR discovery
cohort that were of insufficient DNA yield for genome-wide genotyping were also
included in the replication cohort. The mean age and sex distribution of the 66 NJR
subjects participating in the replication cohort was similar (age 50 ± 14 years, 59
(89%) females) to that participating in the NJR discovery cohort. Subject overlap
between the discovery and replication populations, and between the replication
cohorts was excluded using individual patient identifiers and by cross-referencing
to the NJR dataset. Case duplication was excluded in the discovery cohort at both
subject ID and genotype quality control stages.
The control population comprised 8016 participants from the UKHLS. A
sample of 3364 UKHLS controls were included in the discovery stage and an
independent sample of 4652 UKHLS controls was used in the replication stage at a
case:control ratio of ~1:4. The proportion of female controls in the discovery stage
was selected to reflect the distribution in cases. All replication and control
participants were of UK European ancestry.
arcOGEN cohort: The arcOGEN dataset comprises 7410 unrelated men and
women with osteoarthritis and 11008 unrelated controls from the UK19. The
osteoarthritis hip strata comprises 3266 cases with symptomatic hip osteoarthritis
and a radiographic KL score ≥2. The arcOGEN study used two different types of
controls: population-based, unrelated UK controls which came from five distinct
sources: the 1958 Birth Cohort (58BC) and the UK Blood Donor Service (UKBS)
from the Wellcome Trust Case Control Consortium 2 (WTCCC2) study, the 1958
Birth Cohort from the Type 1 Diabetes Genetics Consortium (T1DGC) study, the
Avon Longitudinal Study of Parents and Children (ALSPAC) and the People of the
British Isles (PoBI) study (ST1); and unrelated, osteoarthritis-free controls (females
only) from the TwinsUK cohort which comprises twins ascertained to study the
heritability and genetics of age-related diseases48. These unselected twins were
recruited from the general population through national media campaigns in the
UK and shown to be comparable to age-matched population singletons in terms of
disease-related and lifestyle characteristics49.
UK Biobank cohort: The UK Biobank is a prospective cohort of 500,000 men
and women aged between 40 and 69 years at recruitment50. Hospital episode
statistics were used to define case status for osteoarthritis in the UKBB sample.
Inclusion and exclusion criteria were based on the International Statistical
Classification of Diseases and Related Health Problems (ICD) 9 or ICD-10 codes.
In total, 2396 cases were defined with a code for hip osteoarthritis, and no
inflammatory arthritis syndromes or other musculoskeletal disorders. Age-matched
controls were selected on the condition that they did not have any osteoarthritis-
related ICD-9 or ICD-10 codes, or self-reported musculoskeletal disorders or
symptoms.
Genotyping, quality control, and association analyses. DNA from 834 NJR
DDH cases was genotyped using the Illumina HumanCoreExome-24 BeadChip
(Illumina, San Diego, USA). Genotypes were called using Illumina Genome Studio
Gencall. The UKHLS were genotyped on the Illumina HumanCoreExome-12v1-
0_A chip and had previously been called using the same algorithm. After removing
samples and variants with call rate <90%, samples underwent standard quality-
control procedures, with exclusion criteria as follows: (i) call rate <98%, (ii) gender
discrepancy, (iii) excess heterozygosity, (iv) duplicates and/or related, (v) ethnicity
outliers, (vi) Fluidigm concordance (this identity check looks at sample con-
cordance between Illumina and Fluidigm genotypes) (Supplementary Table 9) and
variants with (i) call rate <98%, (ii) Hardy–Weinberg Equilibrium (HWE) P < 1 ×
10−4, (iii) cluster separation score <0.4, (iv) minor allele frequency (MAF) <0.01,
(v) minor allele count (MAC) <4 in cases and controls separately.
Data were pruned for linkage disequilibrium using the clumping function in
PLINK51. Parameters used: (a) significance threshold for index single single-
nucleotide polymorphism (SNP): 1e-4, (b) LD threshold for clumping: 0.20, and (c)
physical distance threshold for clumping: 500 kb.
Following quality-control exclusions, the discovery cohort comprised 770 (693
females) DDH cases and 3364 (3048 females) controls. Power was calculated using
Quanto v1.2.452, assuming a population mean of 0 and a standard deviation (SD)
of 1. We calculated power (at the genome-wide significance threshold P= 5 × 10-8)
to detect an effect size of 1 SD by fixing the sample size to the post-QC discovery
sample, which gave >80% power to detect common variants with moderate effect
size (Supplementary Fig. 5). Following QC checks at both the sample and SNP
level, 256,867 overlapping variants were tested for association with DDH using
SNPTEST v253 under an additive model and using a maximum likelihood ratio
test. Association testing on the X chromosome assumes a model of full X
inactivation where pseudo-autosomal regions on the X were treated like autosomes.
The Y chromosome was not included in the analysis. Cluster plots of all prioritised
variants were examined in cases and controls separately to minimise the possibility
of spurious association due to genotyping error. Independent variants with P < 1 ×
10−4 in the discovery set were selected for replication using the clumping function
in PLINK.
De novo genotyping (prioritised variants genotyped in independent cohorts) in
the 1129 replication cases was conducted using the iPLEX® Assay and the
MassARRAY® System (Agena Bioscience, Inc). Variants with poor Agena design
metrics were replaced with highly correlated proxies. Sample exclusions were based
on sex inconsistencies and a sample call rate <80%. Variants with a call rate <90%
and exact HWE P < 1 × 10−6 were also excluded. Case control association analysis
in the replication cohort of 1129 (1004 females) cases and 4652 (2527 females)
controls was performed under an additive genetic model using SNPTEST v2. When
the replication analysis was performed excluding the 66 NJR subjects who failed
genome-wide genotyping QC, the findings were similar (Supplementary Table 10).
Finally, a fixed-effects meta-analysis across the discovery and replication datasets
was conducted using GWAMA54, comprising a total of 1899 cases and 8016
controls. Genome-wide significance was defined as P < 5.0 × 10−8. Conditional
single-variant association analyses were performed in SNPTEST v2 and were used
to identify statistical independence. SNPTEST performs conditioning of a signal by
adding any potentially dependent SNP as a covariate in the analysis. It then tests
for a genetic effect over and above the phenotypic variability that is explained by
the covariate(s). A variant was considered independent of the index SNP if the pre-
and post-conditioning P-value difference was lower than two orders of magnitude.
We repeated the analysis by adjusting for the first 10 principal components to
guard against population stratification. We observed no qualitative difference and
report the results of the unadjusted analysis. Since DDH prevalence varies widely
between populations, we applied multidimensional scaling analyses to characterise
our samples (cases and controls) in the context of broader global diversity and
further ensure the homogeneity of the tested cohort. As shown in Supplementary
Fig. 6 our cohort formed a well-defined cluster with GBR population of 1000
Genomes Project.
Estimation of heritability. We applied the genome-wide complex trait analysis
(GCTA) approach to estimate the proportion of phenotypic variance in DDH
susceptibility that is explained by genome-wide autosomal SNPs17, assuming a
DDH prevalence of 3.6 per 100 live births in the UK2, and using an MAF cut-off of
0.01. GCTA uses a genetic relationship matrix (GRM) of pairs of samples as input
for the restricted maximum likelihood (REML) analysis to estimate narrow sense
heritability (h2). GCTA also converts h2 to liability-scale heritability by applying
the transformation described by Lee et al.55, to make the estimates comparable with
those for quantitative traits. An alternative approach based on phenotype
correlation–genotype correlation (PCGC)56 regression has been proposed to avoid
biases in REML estimation of heritability in the context of ascertained case–control
studies. Here, we applied both GCTA and PCGC methodologies in order to vali-
date our results and ensure that the heritability estimates did not suffer from
case–control ascertainment bias. The sibling relative risk ratio and liability-scale
variance explained were calculated according to the methods described by Morris
et al.57. To investigate if the DDH strongly sex-linked condition is due to variation
in genomic DNA, we further partitioned the genetic variance onto individual
chromosomes and then compared them to heritability estimates of chromosome X.
In this analysis, GCTA uses a joint analysis (all the chromosomes are fitted in one
model) to protect against inter-chromosomal correlations and report the estimates
of variance explained by different chromosomes independently of each other.
GCTA contains built-in options for GRM and heritability estimation for the X
chromosome and assumes a model of full X inactivation58.
Fine-mapping. In order to fine-map the replicating association signals, we used
association statistics from imputed genotypes in determining the credible set, since
an assumption of fine-mapping is that the causal variant is among the variants
tested. All variants within 500 kb of the three replicating lead SNPs were pre-
phased in SHAPEITv259 and the resulting haplotypes were imputed with
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IMPUTE260 using 1000 Genomes Project61 combined with UK10K Project62 data
as the reference panel. Post-imputation quality control (QC) criteria for SNP
exclusion were HWE P-value <1.0 × 10−4 and imputation info score <0.4. We then
applied a method that assigns a relative “probability of regulatory function” (PRF)
score among candidate causal variants, reweighting association statistics based on
epigenomic annotations, and delineating the 95% probability set of likely causal
variants. We collected a set of 70 genomic and epigenomic annotations, primarily
Gencode gene annotations (v19), FANTOM transcription start sites and enhan-
cers63,64, and imputed Roadmap Epigenomics histone marks, DNase hypersensi-
tivity, and ChromHMM genome segmentations for the lymphoblastoid cell line
epigenome (GM12878)65,66. We used the fgwas software67 to train a Bayesian
hierarchical model to compute enrichment of eQTLs in these annotations based on
summary statistics from the Geuvadis RNA sequencing project68. We used forward
stepwise selection followed by cross-validation to arrive at a combined model with
37 annotations and their associated enrichments. The respective annotations from
119 Roadmap epigenomes were used to compute PRF scores for each variant at the
new loci in each of the 119 epigenomes. At each locus we defined the credible set of
causal variants using the WTCCC method with approximate Bayes factors (BF)69,
where SNP k’s posterior probability of being causal is BFk=
P
j
BFj. Beginning with
the most associated SNP, SNPs are sequentially added to the set until the combined
probability is ≥95%. We then selected the top four epigenomes based on the
maximum regulatory score among variants in the 95% credible set, and examined
the regulatory annotations for variants in the credible set.
Gene-based analyses. In order to quantify the degree of association each gene has
with the phenotype and understand the potential functional effects of the identified
variants, we used the GWAS results to perform gene-based enrichment analyses in
MAGMA v1.0318 to identify the joint association of all markers in a given gene
with the phenotype. We used all 19,427 protein-coding genes from the NCBI 37.3
gene definitions and each gene was assigned the SNPs located between the gene’s
start and stop sites. We used all variants that passed QC and after SNP annotation
there were 17,516 genes that were covered by at least one SNP. Gene-based analysis
was then carried out based on a multiple principal components regression model
that accounts for linkage disequilibrium between SNPs, using an F-test to compute
the gene-based P-value (self-contained P-value). P-values generated by MAGMA
are not corrected for multiple testing. Since Bonferroni correction is conservative
when variables (genes) are correlated, MAGMA provides a built-in FWER method
which uses a permutation procedure to obtain P-values corrected for multiple
testing. In all, 10,000 permutations were used in the analysis and the significance
threshold was set at α= 0.05 (FWER threshold= 2.29−07).
Genetic overlap with hip osteoarthritis. Polygenic risks scores were created for
all genotyped participants to test for shared genetic aetiology with idiopathic hip
osteoarthritis. Polygenic risk scores were calculated as the summation of an indi-
vidual’s genotype across many genetic loci using PRSice70, and weighted by the
effect size estimated from two independent UK-based cohorts: arcOGEN hip
osteoarthritis cases versus controls and UK Biobank hip osteoarthritis cases versus
controls, as outlined in the Study Populations section above. Age-matched controls
were selected on the condition that they did not have a hospital diagnosed (ICD-9
or ICD-10) or self-reported musculoskeletal disorders or symptoms. Before
creating the scores, the analysis was restricted to autosomal SNPs and clumping
was used to obtain SNPs in linkage equilibrium with an r2 < 0.1 within a 250-bp
window. Several polygenic scores were created containing SNPs according to the
significance of their association with the hip osteoarthritis. Logistic regression
models were used to test the associations between the polygenic profiles of
hip osteoarthritis and DDH and the first two PCs were used to adjust for
population structure. Nagelkerke’s pseudo-R2 calculation as a measure of the
variance explained and the most predictive threshold are shown in Supplementary
Fig. 4A, B. The genetic correlation between DDH and hip osteoarthritis was esti-
mated using LD score regression by Bulik-Sullivan et al.20. This method exploits
the LD structure of SNPs across the genome and uses the cross-products of
summary test statistics provided from two GWASs at each SNP and then regresses
the cross-product on the LD score to calculate the genetic correlations between
traits/diseases. To test whether DDH has a shared genetic aetiology with 235 other
diseases, we used LD score regression as implemented in the online software
LDHub21 (http://ldsc.broadinstitute.org/). For both analyses we used summary
statistics of the imputed DDH dataset. Genotype imputation was performed on the
Michigan Imputation Server (http://www.haplotype-reference-consortium.org/)
using the updated Haplotype Reference Consortium71. The combined UK10K/1000
Genomes Project haplotype reference panel was used to impute UKBB dataset
centrally (http://www.ukbiobank.ac.uk/wp-content/uploads/2014/04/
imputation_documentation_May2015.pdf).
Data availability. Genome-wide genotype data of the DDH cases and UKHLS
controls have been deposited to the European Genome-Phenome Archive
(www.ebi.ac.uk/ega/home, DDH accession numbers: EGAD00010000766 and
EGAS00001000916; UKHLS accession numbers: EGAD00010000891 and
EGAS00001001232) and of the DDH NJR cases to the NJR data archive
(www.njrcentre.org.uk).
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